// App-Quantinova.ai

LBA45_PR : Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

Researchers

Presenter

  • E.E.Cohen

Principal Investigators

  • K.J.Harrington

  • C.Le Tourneau

  • J.Dinis

  • L.Licitra

  • M-J.Ahn

  • A.Soria

  • J-P.Machiels

  • N.Mach

  • R.Mehra

  • B.Burtness

  • Y.Wang

  • A.J.Tuozzo

  • R.Swaby

  • D.Soulieres

Medical Centers

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Head of Division of Radiotherapy and Imaging, Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, London, UK

  • Department of Medical Oncology, Institut Curie, Saint-Cloud, France

  • Medical Oncology, Instituto Portugues de Oncologia Centro do Porto(IPO-Porto), Porto, Portugal

  • Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori - University of Milan, Milan, Italy

  • Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Seoul, Republic of Korea

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Clinical Biology, Cliniques universitaires St Luc, Brussels, Belgium

  • Clinical Research Unit/Oncology, Hôpitaux Universitaires de Genève, Geneva, Switzerland

  • Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

  • Yale University School of Medicine and Yale Cancer Center, New Haven, CT

  • Biostatistics and Research Design Sciences, Merck & Co., Inc., Kenilworth, NJ, USA

  • Oncology Clinical Development, Merck & Co., Inc., Kenilworth, NJ, USA

  • Medicine, Service of Hematology-Oncology, CHUM, Montreal, QC, Canada

Locations

  • United States

  • United Kingdom

  • France

  • Portugal

  • Italy

  • Spain

  • Belgium

  • Switzerland

  • Canada

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

  • Serpin B3

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

  • Methotrexate

  • Erbitux

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved